EN DE

Halo Collective Inc (HCANF) Fair Value & Analysis

Healthcare · US · Market cap $15.1K

HC Halo Collective Inc logo Halo Collective Inc HCANF · US
Price$0.0001
Fair Value$0.0001
Upside+0.0%
Quality19/100
Watch Halo Collective Inc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 0.0% net margin
Low debt · negative free cash flow
Trails peers (1/8)
Narrow moat 5/100
Evidence: Low Range $0.0001 – $0.0001 Share as image

Fair value as of: Aug 18, 2026

From 1 valuation models · updated today

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$750.00 $0.0001 Fair Value $0.0001 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.

How to read this chart

60‑month range $0.0001 – $750.00 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Halo Collective Inc (HCANF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Trailing-twelve-month revenue stands at $18.3M. Revenue declined 48.1% year over year. Net debt stands at $16.7M. Fundamentals as of Aug 18, 2026

The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, HCANF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0002 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0002 50

Notify me when HCANF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $18.3M
Revenue growth (YoY) -48.1%
Return on equity -141%
Free cash flow −$13.9M FY2022
Operating margin -50.5%
EPS (TTM) $7.95
More key figures
Net debt $16.7M FY2022

Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 19/100

Of which business quality 22 · Market factors (momentum, volatility) 56

Profitability 8
Margins and returns on capital today
Quality Growth 39
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 43
Balance sheet, leverage, solvency risk
Investment 56
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 33
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Halo Collective Inc., together with its subsidiaries, engages in the cultivation, manufacture, transportation, and distribution of cannabis and cannabis extracts in Canada and the United States.

Full company description

Halo Collective Inc., together with its subsidiaries, engages in the cultivation, manufacture, transportation, and distribution of cannabis and cannabis extracts in Canada and the United States. The company offers concentrates, such as shatter, sauce, live resin, badder, hash, rosin, and THC-A crystals; and oils in both in raw and distillated form in various strains and flavors, as well as strain specific cannabinoid ratios and blends. It also packages and sells cannabis derived terpene distillate vapor, botanical terpene, and live resin cartridges. In addition, the company manufactures and sells various edible products, including single and multi-piece chews, cannabis-infused gummies, and syrup-based drinks. It offers its products under Hush and Winberry Farms brand names, through dispensaries and distribution centers in the states of Oregon and California. The company was formerly known as Halo Labs Inc. and changed its name to Halo Collective Inc. in January 2021. Halo Collective Inc. was founded in 2016 and is headquartered in Toronto, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2018 – FY2022 · reported fiscal years

Halo Collective Inc reported revenue of $24.5M in FY2022 versus $10.9M in FY2018, a compound +22.5%/yr. Reported net income was −$83.9M in FY2022.

Growth Quality 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2022)
$24.5M
Latest YoY
−32.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.5%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.6%
Avg. growth/yr (22Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+34.6%
Revenue +22.5%/yr
FY18 $10.9M
FY19 $28.1M
FY20 $21.6M
FY21 $36.2M
FY22 $24.5M
Net income
FY18 −$13.7M
FY19 −$27.6M
FY20 −$41.2M
FY21 −$94.6M
FY22 −$83.9M

Watch HCANF: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Halo Collective Inc Fair Value". https://www.fairvalue-calculator.com/stock/HCANF

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 22 · Bottom 25%
Fair Value upside +0% · Above median
Return on assets -16% · Bottom 25%
Net margin (TTM) 0% · Below median
Operating margin (TTM) -50% · Bottom 25%
Revenue growth -48% · Bottom 25%
Debt / equity 0.30× · Higher than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 33 · sector 7
FUTURE 0 · sector 20
PAST 0 · sector 24
HEALTH 85 · sector 96
DIVIDEND 0 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Halo Collective Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Halo Collective Inc (HCANF) overvalued or undervalued?
As of Aug 18, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% (fairly valued).
What is the fair value of HCANF?
Our model-based fair value for Halo Collective Inc is $0.0001 (as of Aug 18, 2026), built from audited fundamentals. The current price is $0.0001.
What is the quality score of HCANF?
Halo Collective Inc has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Halo Collective Inc (HCANF)?
Halo Collective Inc reported trailing-twelve-month revenue of about $18.3M (latest available figure, as of Aug 18, 2026).
What is the net profit margin of HCANF?
The net profit margin of Halo Collective Inc is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Halo Collective Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.